Although immunotherapy development has improved overall survival among patients with common cancers and has led to important therapeutic advances, rapid expansion of the checkpoint inhibitor class of drugs has been expensive and largely uncoordinated.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: